PRGN-2012 + Bevacizumab for Respiratory Papillomatosis

This trial explores whether combining two treatments, PRGN-2012 (a vaccine-based treatment) and bevacizumab (a drug that inhibits blood vessel growth), can help control recurrent respiratory papillomatosis (RRP). RRP is a rare condition that causes wart-like growths in the airway, making speaking or breathing difficult. The goal is to determine if these treatments can reduce the recurrence of these growths. It is suitable for adults with RRP who have undergone more than two surgeries to remove papillomas or have previously received PRGN-2012 or bevacizumab. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial protocol does not specify if you need to stop taking your current medications. However, you cannot participate if you have taken certain investigational agents or systemic RRP therapies within 4 weeks before starting the study. It's best to discuss your current medications with the study team to ensure eligibility.

Research has shown that using PRGN-2012 with bevacizumab appears promising for safety. Bevacizumab, previously used, is generally well-tolerated, with mild and manageable side effects in about 38% of patients. PRGN-2012, a vaccine-based treatment, has also been studied and found to be safe. In one study, more than half of the patients treated with PRGN-2012 experienced a complete response without major safety issues. Although using these treatments together is new, both have demonstrated acceptable safety in past research.¹²³⁴⁵

Researchers are excited about the combination of PRGN-2012 and Bevacizumab for respiratory papillomatosis because it offers a novel approach to tackling this challenging condition. Unlike traditional treatments, which often involve repeated surgeries to remove papillomas, PRGN-2012 is a therapeutic vaccine designed to stimulate the immune system to target and destroy the HPV-infected cells causing the papillomas. Bevacizumab, on the other hand, is an angiogenesis inhibitor that works by cutting off the blood supply to the papillomas, potentially reducing their growth. Together, these treatments might offer a more effective and less invasive option for patients who currently rely on surgical interventions.

Research has shown that PRGN-2012, a vaccine-based treatment, holds promise for treating recurrent respiratory papillomatosis (RRP). In studies, 83% of patients experienced a complete response, with their papillomas either significantly improving or disappearing. PRGN-2012 also reduced the need for surgeries in 86% of patients, helping to prevent the recurrence of papillomas. Bevacizumab, another treatment in this trial, has shown effectiveness for RRP with a response rate of about 71%. This drug works by affecting blood vessel growth, which can help stop the spread of papillomas. Participants in this trial will receive both PRGN-2012 and Bevacizumab together, aiming to control RRP and reduce the frequency of surgeries.¹²³⁴⁵